Inclusion Criteria: Nephrotic patients - no intervention  Age 18-79 years Estimated Glomerular Filtration Rate (eGFR) > 49 mL/min/1.73 m2 P-albumin < 30 g/L U-Albumin excretion > 2.2 g/day Known glomerular disease including membranous nephropathy, which may cause nephrotic syndrome or diagnostically unresolved nephrotic syndrome with a planed kidney biopsy.  Inclusion Criteria: Nephrotic patients treated with Dalteparin  Age 18-79 years eGFR > 49 mL/min/1.73 m2 P-albumin < 25 g/L U-Albumin excretion > 2.2 g/day Known glomerular disease including membranous nephropathy, which may cause nephrotic syndrome or diagnostically unresolved nephrotic syndrome with a planed kidney biopsy.  Inclusion Criteria: Nephrotic patients treated with Apixaban  Age 18-79 years eGFR > 49 mL/min/1.73 m2 P-albumin < 25 g/L U-Albumin excretion > 2.2 g/day Membranous Nephropathy  Inclusion Criteria: Patients with atrial fibrillation treated with Apixaban  Age 18-79 years eGFR > 49 mL/min/1.73 m2 P-albumin > 36 g/L U-Albumin excretion < 300 mg/day Atrial Fibrillation  Exclusion Criteria:  Contraindication to Apixaban Contraindication to Dalteparin Known allergy or intolerance to Apixaban Known allergy or intolerance to Dalteparin Treatment with anticoagulation for other reasons. Treatment with cyclooxygenase-1-inhibitors or Adenosine Diphosphate (ADP) receptor inhibitors. Known acquired or congenital coagulation defect non related to nephrotic syndrome or thromboembolic disease within 3 months. Known diabetes mellitus. Lack of compliance, comorbidity or other conditions that, in the patients unfit to participate in the trial. Pregnancy